The CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting.

Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey

Novello, Silvia;
2019-01-01

Abstract

The CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting.
2019
136
145
147
Fractionation; Limited-stage; Small-cell lung cancer; Thoracic radiotherapy
Levy, Antonin; Hendriks, Lizza E L; Le Péchoux, Cécile; Falk, Sally; Besse, Benjamin; Novello, Silvia; Dingemans, Anne-Marie C; Hasan, Baktiar; Reck, Martin; Berghmans, Thierry; Faivre-Finn, Corinne
File in questo prodotto:
File Dimensione Formato  
Current management of limited-stage SCLC and CONVERT trial impact_ Results of the EORTC Lung Cancer Group survey _ Elsevier Enhanced Reader.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 2.05 MB
Formato Adobe PDF
2.05 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1711987
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 16
social impact